Skip to main content

Schizophrenia & Psychotic Disorders

More than a third of people who experienced psychosis with cannabis use later transitioned to schizophrenia, according to a systematic review and meta-analysis published online in Schizophrenia Bulletin.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.
A new study identified a dose-response association between longer amounts of time spent in low-income conditions during childhood and a higher risk of developing schizophrenia after age 15.
People with schizophrenia with primary negative symptoms had significantly wider oral palates compared with patients with nondeficit schizophrenia as well as control subjects in a study published online in Schizophrenia Bulletin.
The US Food and Drug Administration (FDA) has approved a transdermal patch formulation of asenapine (Secuado) as the first patch for the treatment of adults with schizophrenia, Noven Pharmaceuticals, Inc. announced.

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive…

What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top